Paul Shore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Paul Shore has a total of 148 co-authors. Here are the top co-authors by number of shared publications:
Andrew D. Sharrocks
Department of Biochemistry and Genetics, The Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne, NE2 4HH, UK
6 shared publications- Alan J. Whitmarsh
University of Manchester
4 shared publications - Wensheng Deng
School of Life Science and Health, Wuhan University of Science and Technology, Wuhan, 430065, China
4 shared publications - Hannah Harrison
Division of Cancer Sciences, University of Manchester, Oglesby Cancer Research Building, Manchester Cancer Research Centre, Wilmslow Road, M20 4GJ, UK
3 shared publications - Jonathan Peter Waltho
University of Manchester
3 shared publications Juan Wang
College of Life Science and Health, Wuhan University of Science and Technology, Wuhan 430065, China
3 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by Springer Nature in BMC Medical Education
- Vol. 26 (1)
Teaching at scale: a mixed-methods study of team-based learning analytics to enable early support in medical education
Background: Medical schools are under increasing pressure to teach larger cohorts while maintaining an excellent student experience. The University of Manchester replaced Problem-Based Learning (PBL) with Team-Based Learning (TBL) in 2023 to meet growing demand for medical education. While the educational effectiveness of TBL is well established, this study evaluated how the routine data generated within large-scale TBL could be potentially used to support early intervention, monitor curriculum quality, and validate peer assessment processes. Methods: We conducted a prospective mixed-methods evaluation of two consecutive Year-1 medical cohorts at a large UK medical school (2023–24, n = 435; 2024–25, n = 426). Data included TBL individual readiness assurance test (iRAT) scores, student experience surveys, operational measures, and end-of-semester examination results. In the second year, the 50 lowest-performing students after four teaching themes were identified using iRAT data and offered tailored academic and wellbeing support through their academic advisors. Results: TBL maintained high student satisfaction (74% rated sessions “excellent”) whilst simultaneously reducing weekly staff facilitator hours by 63% (160 h vs. 59 h) and room use by 84% (80 h of bookings vs. 13). Student individual weekly performance, as measured by iRAT scores, was strongly predictive of summative performance (R²≈0.38–0.41) and this finding is reproducible over consecutive years. Theme-level variation in iRAT performance also identified differences in content difficulty and alignment, providing a programme-level indicator of curriculum quality and areas of weaker delivery. Early identification and intervention of struggling students increased semester performance by 20% ( p < 0.0001) among the bottom 50 students, improved summative exam marks by 5%, and reduced exam failure rate by 41%, without inflating whole cohort attainment. Conclusions: This study shows how routine TBL data can function as a scalable analytics system to support early intervention, continuous curriculum monitoring, and quality assurance of peer assessment, while also reducing operational demands. These findings provide a transferable model for institutions seeking to expand capacity while maintaining educational quality and equity.
- 15 June 2026
- Published by Springer Nature in BMC Medical Education
- Vol. 26 (1)
Open AccessTeaching at scale: a mixed-methods study of team-based learning analytics to enable early support in medical education
Background: Medical schools are under increasing pressure to teach larger cohorts while maintaining an excellent student experience. The University of Manchester replaced Problem-Based Learning (PBL) with Team-Based Learning (TBL) in 2023 to meet growing demand for medical education. While the educational effectiveness of TBL is well established, this study evaluated how the routine data generated within large-scale TBL could be potentially used to support early intervention, monitor curriculum quality, and validate peer assessment processes. Methods: We conducted a prospective mixed-methods evaluation of two consecutive Year-1 medical cohorts at a large UK medical school (2023–24, n = 435; 2024–25, n = 426). Data included TBL individual readiness assurance test (iRAT) scores, student experience surveys, operational measures, and end-of-semester examination results. In the second year, the 50 lowest-performing students after four teaching themes were identified using iRAT data and offered tailored academic and wellbeing support through their academic advisors. Results: TBL maintained high student satisfaction (74% rated sessions “excellent”) whilst simultaneously reducing weekly staff facilitator hours by 63% (160 h vs. 59 h) and room use by 84% (80 h of bookings vs. 13). Student individual weekly performance, as measured by iRAT scores, was strongly predictive of summative performance (R²≈0.38–0.41) and this finding is reproducible over consecutive years. Theme-level variation in iRAT performance also identified differences in content difficulty and alignment, providing a programme-level indicator of curriculum quality and areas of weaker delivery. Early identification and intervention of struggling students increased semester performance by 20% ( p < 0.0001) among the bottom 50 students, improved summative exam marks by 5%, and reduced exam failure rate by 41%, without inflating whole cohort attainment. Conclusions: This study shows how routine TBL data can function as a scalable analytics system to support early intervention, continuous curriculum monitoring, and quality assurance of peer assessment, while also reducing operational demands. These findings provide a transferable model for institutions seeking to expand capacity while maintaining educational quality and equity.
- Open Access
- 1 April 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (14) , 4617-4630
The transcription factor Sp1 modulates RNA polymerase III gene transcription by controlling BRF1 and GTF3C2 expression in human cells
- 1 April 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (14) , 4617-4630
Open AccessThe transcription factor Sp1 modulates RNA polymerase III gene transcription by controlling BRF1 and GTF3C2 expression in human cells
- Open Access
- 31 January 2020
- Published by Springer Nature in Oncogene
- Vol. 39 (12) , 2624-2637
A role for CBFβ in maintaining the metastatic phenotype of breast cancer cells
Epithelial to mesenchymal transition (EMT) is a dynamic process that drives cancer cell plasticity and is thought to play a major role in metastasis. Here we show, using MDA-MB-231 cells as a model, that the plasticity of at least some metastatic breast cancer cells is dependent on the transcriptional co-regulator CBFβ. We demonstrate that CBFβ is essential to maintain the mesenchymal phenotype of triple-negative breast cancer cells and that CBFβ-depleted cells undergo a mesenchymal to epithelial transition (MET) and re-organise into acini-like structures, reminiscent of those formed by epithelial breast cells. We subsequently show, using an inducible CBFβ system, that the MET can be reversed, thus demonstrating the plasticity of CBFβ-mediated EMT. Moreover, the MET can be reversed by expression of the EMT transcription factor Slug whose expression is dependent on CBFβ. Finally, we demonstrate that loss of CBFβ inhibits the ability of metastatic breast cancer cells to invade bone cell cultures and suppresses their ability to form bone metastases in vivo. Together our findings demonstrate that CBFβ can determine the plasticity of the metastatic cancer cell phenotype, suggesting that its regulation in different micro-environments may play a key role in the establishment of metastatic tumours.
- 31 January 2020
- Published by Springer Nature in Oncogene
- Vol. 39 (12) , 2624-2637
Open AccessA role for CBFβ in maintaining the metastatic phenotype of breast cancer cells
Epithelial to mesenchymal transition (EMT) is a dynamic process that drives cancer cell plasticity and is thought to play a major role in metastasis. Here we show, using MDA-MB-231 cells as a model, that the plasticity of at least some metastatic breast cancer cells is dependent on the transcriptional co-regulator CBFβ. We demonstrate that CBFβ is essential to maintain the mesenchymal phenotype of triple-negative breast cancer cells and that CBFβ-depleted cells undergo a mesenchymal to epithelial transition (MET) and re-organise into acini-like structures, reminiscent of those formed by epithelial breast cells. We subsequently show, using an inducible CBFβ system, that the MET can be reversed, thus demonstrating the plasticity of CBFβ-mediated EMT. Moreover, the MET can be reversed by expression of the EMT transcription factor Slug whose expression is dependent on CBFβ. Finally, we demonstrate that loss of CBFβ inhibits the ability of metastatic breast cancer cells to invade bone cell cultures and suppresses their ability to form bone metastases in vivo. Together our findings demonstrate that CBFβ can determine the plasticity of the metastatic cancer cell phenotype, suggesting that its regulation in different micro-environments may play a key role in the establishment of metastatic tumours.
- 1 May 2019
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 17 (5) , 1015-1023
The RUNX Transcriptional Coregulator, CBFβ, Suppresses Migration of ER+ Breast Cancer Cells by Repressing ERα-Mediated Expression of the Migratory Factor TFF1
Core binding factor β (CBFβ), the essential coregulator of RUNX transcription factors, is one of the most frequently mutated genes in estrogen receptor–positive (ER+) breast cancer. Many of these mutations are nonsense mutations and are predicted to result in loss of function, suggesting a tumor suppressor role for CBFβ. However, the impact of missense mutations and the loss of CBFβ in ER+ breast cancer cells have not been determined. Here we demonstrate that missense mutations in CBFβ accumulate near the Runt domain–binding region. These mutations inhibit the ability of CBFβ to form CBFβ–Runx–DNA complexes. We further show that deletion of CBFβ, using CRISPR-Cas9, in ER+ MCF7 cells results in an increase in cell migration. This increase in migration is dependent on the presence of ERα. Analysis of the potential mechanism revealed that the increase in migration is driven by the coregulation of Trefoil factor 1 (TFF1) by CBFβ and ERα. RUNX1–CBFβ acts to repress ERα-activated expression of TFF1. TFF1 is a motogen that stimulates migration and we show that knockdown of TFF1 in CBFβ−/− cells inhibits the migratory phenotype. Our findings reveal a new mechanism by which RUNX1–CBFβ and ERα combine to regulate gene expression and a new role for RUNX1–CBFβ in the prevention of cell migration by suppressing the expression of the motogen TFF1. Implications: Mutations in CBFβ contribute to the development of breast cancer by inducing a metastatic phenotype that is dependent on ER.
- 1 May 2019
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 17 (5) , 1015-1023
The RUNX Transcriptional Coregulator, CBFβ, Suppresses Migration of ER+ Breast Cancer Cells by Repressing ERα-Mediated Expression of the Migratory Factor TFF1
Core binding factor β (CBFβ), the essential coregulator of RUNX transcription factors, is one of the most frequently mutated genes in estrogen receptor–positive (ER+) breast cancer. Many of these mutations are nonsense mutations and are predicted to result in loss of function, suggesting a tumor suppressor role for CBFβ. However, the impact of missense mutations and the loss of CBFβ in ER+ breast cancer cells have not been determined. Here we demonstrate that missense mutations in CBFβ accumulate near the Runt domain–binding region. These mutations inhibit the ability of CBFβ to form CBFβ–Runx–DNA complexes. We further show that deletion of CBFβ, using CRISPR-Cas9, in ER+ MCF7 cells results in an increase in cell migration. This increase in migration is dependent on the presence of ERα. Analysis of the potential mechanism revealed that the increase in migration is driven by the coregulation of Trefoil factor 1 (TFF1) by CBFβ and ERα. RUNX1–CBFβ acts to repress ERα-activated expression of TFF1. TFF1 is a motogen that stimulates migration and we show that knockdown of TFF1 in CBFβ−/− cells inhibits the migratory phenotype. Our findings reveal a new mechanism by which RUNX1–CBFβ and ERα combine to regulate gene expression and a new role for RUNX1–CBFβ in the prevention of cell migration by suppressing the expression of the motogen TFF1. Implications: Mutations in CBFβ contribute to the development of breast cancer by inducing a metastatic phenotype that is dependent on ER.
- Open Access
RUNX/CBFβ transcription factor complexes promote the phenotypic plasticity of metastatic breast cancer cells
Epithelial to mesenchymal transition (EMT) is a dynamic process that drives cancer cell plasticity and is thought to play a major role in metastasis. Here we show that the plasticity of metastatic breast cancer cells can be promoted by the activity of the RUNX transcription factors. We demonstrate that the RUNX co-regulator CBFβ is essential to maintain the mesenchymal phenotype of triple-negative breast cancer cells and that CBFβ-depleted cells undergo a mesenchymal to epithelial transition (MET) and re-organise into acini-like structures, reminiscent of those formed by epithelial breast cells. We subsequently show, using an inducible CBFβ system, that the MET can be reversed, thus demonstrating the plasticity of RUNX/CBFβ-mediated EMT. Moreover, the MET can be reversed by expression of the EMT transcription factor Slug whose expression is dependent on CBFβ, RUNX1 and RUNX2. Finally, we demonstrate that loss of CBFβ inhibits the ability of metastatic breast cancer cells to invade bone cell cultures and suppresses their ability to form bone metastases in vivo . Together our findings demonstrate that the RUNX/CBFβ complexes can determine the plasticity of the metastatic cancer cell phenotypes, suggesting that their regulation in different micro-environments may play a key role in the establishment of metastatic tumours.
Open AccessRUNX/CBFβ transcription factor complexes promote the phenotypic plasticity of metastatic breast cancer cells
Epithelial to mesenchymal transition (EMT) is a dynamic process that drives cancer cell plasticity and is thought to play a major role in metastasis. Here we show that the plasticity of metastatic breast cancer cells can be promoted by the activity of the RUNX transcription factors. We demonstrate that the RUNX co-regulator CBFβ is essential to maintain the mesenchymal phenotype of triple-negative breast cancer cells and that CBFβ-depleted cells undergo a mesenchymal to epithelial transition (MET) and re-organise into acini-like structures, reminiscent of those formed by epithelial breast cells. We subsequently show, using an inducible CBFβ system, that the MET can be reversed, thus demonstrating the plasticity of RUNX/CBFβ-mediated EMT. Moreover, the MET can be reversed by expression of the EMT transcription factor Slug whose expression is dependent on CBFβ, RUNX1 and RUNX2. Finally, we demonstrate that loss of CBFβ inhibits the ability of metastatic breast cancer cells to invade bone cell cultures and suppresses their ability to form bone metastases in vivo . Together our findings demonstrate that the RUNX/CBFβ complexes can determine the plasticity of the metastatic cancer cell phenotypes, suggesting that their regulation in different micro-environments may play a key role in the establishment of metastatic tumours.
- Open Access
- 20 June 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-9
HIF1-alpha expressing cells induce a hypoxic-like response in neighbouring cancer cells
Hypoxia stimulates metastasis in cancer and is linked to poor patient prognosis. In tumours, oxygen levels vary and hypoxic regions exist within a generally well-oxygenated tumour. However, whilst the heterogeneous environment is known to contribute to metastatic progression, little is known about the mechanism by which heterogeneic hypoxia contributes to cancer progression. This is largely because existing experimental models do not recapitulate the heterogeneous nature of hypoxia. The primary effector of the hypoxic response is the transcription factor Hypoxia inducible factor 1-alpha (HIF1-alpha). HIF1-alpha is stabilised in response to low oxygen levels in the cellular environment and its expression is seen in hypoxic regions throughout the tumour. We have developed a model system in which HIF1-alpha can be induced within a sub-population of cancer cells, thus enabling us to mimic the effects of heterogeneic HIF1-alpha expression. We show that induction of HIF1-alpha not only recapitulates elements of the hypoxic response in the induced cells but also results in significant changes in proliferation, gene expression and mammosphere formation within the HIF1-alpha negative population. These findings suggest that the HIF1-alpha expressing cells found within hypoxic regions are likely to contribute to the subsequent progression of a tumour by modifying the behaviour of cells in the non-hypoxic regions of the local micro-environment.
- 20 June 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-9
Open AccessHIF1-alpha expressing cells induce a hypoxic-like response in neighbouring cancer cells
Hypoxia stimulates metastasis in cancer and is linked to poor patient prognosis. In tumours, oxygen levels vary and hypoxic regions exist within a generally well-oxygenated tumour. However, whilst the heterogeneous environment is known to contribute to metastatic progression, little is known about the mechanism by which heterogeneic hypoxia contributes to cancer progression. This is largely because existing experimental models do not recapitulate the heterogeneous nature of hypoxia. The primary effector of the hypoxic response is the transcription factor Hypoxia inducible factor 1-alpha (HIF1-alpha). HIF1-alpha is stabilised in response to low oxygen levels in the cellular environment and its expression is seen in hypoxic regions throughout the tumour. We have developed a model system in which HIF1-alpha can be induced within a sub-population of cancer cells, thus enabling us to mimic the effects of heterogeneic HIF1-alpha expression. We show that induction of HIF1-alpha not only recapitulates elements of the hypoxic response in the induced cells but also results in significant changes in proliferation, gene expression and mammosphere formation within the HIF1-alpha negative population. These findings suggest that the HIF1-alpha expressing cells found within hypoxic regions are likely to contribute to the subsequent progression of a tumour by modifying the behaviour of cells in the non-hypoxic regions of the local micro-environment.
- Open Access
- 1 July 2017
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 292 (28) , 11873-11885
A transcription factor IIA-binding site differentially regulates RNA polymerase II-mediated transcription in a promoter context-dependent manner
- 1 July 2017
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 292 (28) , 11873-11885
Open AccessA transcription factor IIA-binding site differentially regulates RNA polymerase II-mediated transcription in a promoter context-dependent manner
- 16 March 2017
- Published by Springer Nature
- Vol. 962, 353-368
Runx Genes in Breast Cancer and the Mammary Lineage
A full understanding of RUNX gene function in different epithelial lineages has been thwarted by the lethal phenotypes observed when constitutively knocking out these mammalian genes. However temporal expression of the Runx genes throughout the different phases of mammary gland development is indicative of a functional role in this tissue. A few studies have emerged describing how these genes impact on the fate of mammary epithelial cells by regulating lineage differentiation and stem/progenitor cell potential, with implications for the transformed state. The importance of the RUNX/CBFβ core factor binding complex in breast cancer has very recently been highlighted with both RUNX1 and CBFβ appearing in a comprehensive gene list of predicted breast cancer driver mutations. Nonetheless, the evidence to date shows that the RUNX genes can have dualistic outputs with respect to promoting or constraining breast cancer phenotypes, and that this may be aligned to individual subtypes of the clinical disease. We take this opportunity to review the current literature on RUNX and CBFβ in the normal and neoplastic mammary lineage while appreciating that this is likely to be the tip of the iceberg in our knowledge.
- 16 March 2017
- Published by Springer Nature
- Vol. 962, 353-368
Runx Genes in Breast Cancer and the Mammary Lineage
A full understanding of RUNX gene function in different epithelial lineages has been thwarted by the lethal phenotypes observed when constitutively knocking out these mammalian genes. However temporal expression of the Runx genes throughout the different phases of mammary gland development is indicative of a functional role in this tissue. A few studies have emerged describing how these genes impact on the fate of mammary epithelial cells by regulating lineage differentiation and stem/progenitor cell potential, with implications for the transformed state. The importance of the RUNX/CBFβ core factor binding complex in breast cancer has very recently been highlighted with both RUNX1 and CBFβ appearing in a comprehensive gene list of predicted breast cancer driver mutations. Nonetheless, the evidence to date shows that the RUNX genes can have dualistic outputs with respect to promoting or constraining breast cancer phenotypes, and that this may be aligned to individual subtypes of the clinical disease. We take this opportunity to review the current literature on RUNX and CBFβ in the normal and neoplastic mammary lineage while appreciating that this is likely to be the tip of the iceberg in our knowledge.
- Open Access
- 1 November 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (48) , 25239-25246
Cytoskeletal Filamin A Differentially Modulates RNA Polymerase III Gene Transcription in Transformed Cell Lines
- 1 November 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (48) , 25239-25246
Open AccessCytoskeletal Filamin A Differentially Modulates RNA Polymerase III Gene Transcription in Transformed Cell Lines
- 14 September 2014
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 74 (18) , 5277-5286
Runx2 Is a Novel Regulator of Mammary Epithelial Cell Fate in Development and Breast Cancer
Regulators of differentiated cell fate can offer targets for managing cancer development and progression. Here, we identify Runx2 as a new regulator of epithelial cell fate in mammary gland development and breast cancer. Runx2 is expressed in the epithelium of pregnant mice in a strict temporally and hormonally regulated manner. During pregnancy, Runx2 genetic deletion impaired alveolar differentiation in a manner that disrupted alveolar progenitor cell populations. Conversely, exogenous transgenic expression of Runx2 in mammary epithelial cells blocked milk production, suggesting that the decrease in endogenous Runx2 observed late in pregnancy is necessary for full differentiation. In addition, overexpression of Runx2 drove epithelial-to-mesenchymal transition–like changes in normal mammary epithelial cells, whereas Runx2 deletion in basal breast cancer cells inhibited cellular phenotypes associated with tumorigenesis. Notably, loss of Runx2 expression increased tumor latency and enhanced overall survival in a mouse model of breast cancer, with Runx2-deficient tumors exhibiting reduced cell proliferation. Together, our results establish a previously unreported function for Runx2 in breast cancer that may offer a novel generalized route for therapeutic interventions. Cancer Res; 74(18); 5277–86. ©2014 AACR.
- 14 September 2014
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 74 (18) , 5277-5286
Runx2 Is a Novel Regulator of Mammary Epithelial Cell Fate in Development and Breast Cancer
Regulators of differentiated cell fate can offer targets for managing cancer development and progression. Here, we identify Runx2 as a new regulator of epithelial cell fate in mammary gland development and breast cancer. Runx2 is expressed in the epithelium of pregnant mice in a strict temporally and hormonally regulated manner. During pregnancy, Runx2 genetic deletion impaired alveolar differentiation in a manner that disrupted alveolar progenitor cell populations. Conversely, exogenous transgenic expression of Runx2 in mammary epithelial cells blocked milk production, suggesting that the decrease in endogenous Runx2 observed late in pregnancy is necessary for full differentiation. In addition, overexpression of Runx2 drove epithelial-to-mesenchymal transition–like changes in normal mammary epithelial cells, whereas Runx2 deletion in basal breast cancer cells inhibited cellular phenotypes associated with tumorigenesis. Notably, loss of Runx2 expression increased tumor latency and enhanced overall survival in a mouse model of breast cancer, with Runx2-deficient tumors exhibiting reduced cell proliferation. Together, our results establish a previously unreported function for Runx2 in breast cancer that may offer a novel generalized route for therapeutic interventions. Cancer Res; 74(18); 5277–86. ©2014 AACR.